| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000047012 |
| Receipt No. | R000053637 |
| Scientific Title | Analysis and prognostic significance of biological samples from patients with severe heart failure requiring ventricular assist device (VAD) and heart transplantation |
| Date of disclosure of the study information | 2022/02/26 |
| Last modified on | 2022/08/28 (Ver. 2) |
| Basic information | ||
| Public title | Analysis and prognostic significance of biological samples from patients with severe heart failure requiring ventricular assist device (VAD) and heart transplantation | |
| Acronym | Research on biological samples from patients with severe heart failure requiring VAD and heart transplantation | |
| Scientific Title | Analysis and prognostic significance of biological samples from patients with severe heart failure requiring ventricular assist device (VAD) and heart transplantation | |
| Scientific Title:Acronym | Research on biological samples from patients with severe heart failure requiring VAD and heart transplantation | |
| Region |
|
|
| Condition | ||
| Condition | Heart failure | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | We will accumulate clinical information and biological samples from patients with VAD and severe heart failure requiring heart transplantation, and conduct pathological analysis as well as comprehensive analysis at each level of genome, RNA, protein, epigenome, and mitochondria (multi-layered omics analysis) to identify key factors in the pathogenesis and pathogenesis of myocardial damage and complications. In addition, we aim to identify key factors in the pathogenesis of myocardial disorders and complications. In addition, we will examine the relationship with prognosis by examining endpoints on a continuous and long-term basis. |
| Basic objectives2 | Others |
| Basic objectives -Others | N/A |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Relationship between findings from various biological samples and incidence of all-cause mortality, cardiovascular death, and heart failure hospitalization |
| Key secondary outcomes | Relationship between findings from various biological samples and infections (driveline infection, pocket infection, sepsis, mediastinal sinusitis, etc.), heart failure (pump dysfunction, right heart failure), device failure (pump, controller), device thrombosis, hemolysis, arrhythmia, multiple organ failure (liver, kidney, lung, etc.), cerebral neuropathy (stroke, cerebral hemorrhage), gastrointestinal bleeding, and aortic regurgitation.
The relationship between findings from various biological samples and acute complications (acute rejection, graft failure, infection, multi-organ failure, renal failure) and chronic complications (transplant coronary artery lesions, malignancy, lymphoma) after heart transplantation. Relationship between findings from various biological samples and patient background, cardiac MRI, cardiac PET, and blood test data. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Age 18 years or older at the time of obtaining consent
(2) Those who have freely and voluntarily consented to participate in this research for research subjects using specimens, and those who do not refuse to participate in the research for research subjects using only medical information. |
|||
| Key exclusion criteria | (1) Persons who are judged by the Principal Investigator to be inappropriate as research subjects. | |||
| Target sample size | 70 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Faculty of Medicine and Graduate School of Medicine, Hokkaido University | ||||||
| Division name | Department of Cardiovascular Medicine | ||||||
| Zip code | 060-8638 | ||||||
| Address | Kita-15, Nishi-7, Kita-ku, Sapporo, Japan | ||||||
| TEL | 011-706-6973 | ||||||
| tnagai@huhp.hokudai.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Faculty of Medicine and Graduate School of Medicine, Hokkaido University | ||||||
| Division name | Department of Cardiovascular Medicine | ||||||
| Zip code | 0608638 | ||||||
| Address | Kita-15, Nishi-7, Kita-ku, Sapporo, Japan | ||||||
| TEL | 0117066973 | ||||||
| Homepage URL | |||||||
| stakenaka1102@gmail.com | |||||||
| Sponsor | |
| Institute | Hokkaido University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Non profit foundation |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ethical Review Board for Life Science and Medical Research, Hokkaido University Hospital |
| Address | Kita-14, Nishi-5, Kita-ku, Sapporo, Japan |
| Tel | 011-706-7636 |
| crjimu@huhp.hokudai.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道大学病院(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | none |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000053637 |